report cf franchis revenu vs consensu non-
gaap ep vs consensu base strong revenu total
revenu guidanc increas nda submit juli
earli launch anticip expect industry-lead growth
remain top larg cap pick
vertex report cystic fibrosi cf franchis revenu q/q
y/i ahead consensu estim revenu includ
kalydeco sale q/q y/i orkambi q/q y/i
symdeko revenu q/q y/i cf franchis revenu exhibit
particularli strong q/q y/i growth driven on-going launch symdeko
 symkevi ex-u notabl germani new expand label
orkambi kalydeco indic materi chang channel
inventori combin non-gaap sg vs yield
non-gaap ep ahead consensu
vertex increas guidanc cf revenu
previous base strong trend combin sg
previous reflect up-front payment crispr
kymera non-gaap sg guidanc unchang vertex
revenu guidanc assum sale market compani alreadi achiev
reimburs attain addit fund agreement particularli larger
market like england and/or franc would prompt anoth uptick revenu
guidanc adjust estim consist current trend
new guidanc cf franchis estim increas y/i
non-gaap ep estim increas dcf-base
may vertex announc select elexacaftor next-gener
corrector use tripl therapi regimen combin tezacaftor
ivacaftor choic two next-gener corrector vertex brought
phase base comparison phase
data tripl regimen patient one mutat one minim
function mutat het min addit comparison previous announc
phase data patient two mutat believ tripl therapi
demonstr safeti efficaci profil dramat improv qualiti
life -- like lengthen lifespan -- cystic fibrosi patient least
one allel approxim cystic fibrosi patient least one
allel includ approxim cf patient het min
current effect safe therapi elexacaftor tripl regimen appear
major advanc cystic fibrosi patient
vertex submit nda fda elexacaftor tezacaftor ivacaftor juli
plan submiss ema expect tripl get
prioriti review impli march pdufa given dramat efficaci major unmet
need think possibl tripl could approv pdufa -- kalydeco initi
fda approv came month submiss nda
pleas see page report import disclosur
cftr potenti kalydeco standard care cf patient gate partial loss
function mutat also develop regimen contain kalydeco cftr
corrector lumacaftor tezacaftor potenti address cf patient
harbor least one allel orkambi lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
contain gener corrector well tezacaftor ivacaftor produc impress
ph data fda file made juli eu file follow later
tripl regimen appear repres true breakthrough treatment improv
qualiti life extend life span patient model assum cystic fibrosi
patient one vertex therapi drive nearli franchis sale
dcf-base price target
possibl approv
phase ii data
initi phase ii trial fsg
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi orkambi kalydeco standard
therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener posit phase data
tripl combin regimen incorpor second gener corrector
patient fda file anticip tripl
regimen appear repres true breakthrough treatment improv
qualiti life extend life span cystic fibrosi world-wide moreov
patent protect late vertex franchis long commerci life
early-stag pipelin includ candid antitrypsin defici pain sickl
cell diseas beta-thalassemia focal segment glomerulosclerosi
vertex continu gain approv expand use cf medicin recent
australia orkambi approv children age kalydeco approv
children age month addit symdeko approv children
age submiss plan
asid ema file elexacaftor tripl major mileston
anticip pipelin nonetheless current program
clinic develop mani expect gener meaning data
initi phase ii dose-rang studi once-daili potenti
monotherapi support develop part once-daili tripl clinicaltri gov
list primari complet date june compani plan initi
phase develop once-daili tripl regimen also evalu
combin third-gener corrector tezecaftor phase ii studi
accord clinicaltri gov trial expect complet decemb impli
data earli initi phase program later year
vertex first candid antitrypsin complet sad
mad studi healthi volunt though compani releas phase result
tonight vertex announc base safeti toler pharmacokinet data
studi advanc phase ii dose-rang studi patient two
 mutat phase ii clinic data includ level liver biopsi data expect
base preclin data vertex expect correct fold
reduc aggreg form liver allow protein travel
lung vertex also advanc second small molecul corrector phase
develop risk mitig purpos vertex may take multipl candid phase
ii done cf
vertex crispr initi ph i/ii studi sickl cell diseas beta
thalassemia tonight vertex announc first patient scd dose
first beta thalassemia patient dose think possibl initi data
least one trial could releas
pain vertex identifi sever select inhibitor compani intend
obtain clinic data multipl compound determin best molecul
advanc late-stag develop tonight vertex announc initi phase
trial novel inhibitor
final vertex initi phase studi oral small molecul
mediat focal segment glomerulosclerosi fsg fsg character proteinuria
patient typic progress develop impair kidney function vertex estim
approxim patient fsg homozyg
mutat assum phase data posit vertex plan initi phase ii trial
reduct proteinuria primari endpoint sever inhibitor
candid treatment fsg preclin develop
vertex leader develop candid treat cystic fibrosi model
assum cystic fibrosi patient one vertex therapi
drive almost franchis sale base promis tripl regimen
project revenu compound-annual-growth-rate non-gaap ep compound-annual-growth-rate
highest larg cap biotech patent protect exclus late
tripl regimen long lucr commerci live moreov
anticip potenti non-cf pipelin becom clear next
month proof-of-concept data like number program larg cap
univers middl growth prospect think fundament posit vertex
must biotech larg cap growth investor expect vertex stock appreci
price target tripl regimen approach commerci launch vertex non-cf
pipelin gener proof-of-concept dcf-base price target
vertex leader discoveri develop candid treat cystic
fibrosi vertex first cystic fibrosi commerci product kalydeco ivacaftor
cftr potenti compound kalydeco approv fda
januari patient gate mutat mutat
addit residu function mutat subsequ ad label
seri supplement approv estim kalydeco achiev
world-wide sale patient gate
defect partial loss function cftr mutat vertex also develop
regimen contain kalydeco cftr corrector lumacaftor tezacaftor
potenti address cf patient harbor least one allel
orkambi lumacaftor ivacaftor succeed two pivot trial june
approv juli symdeko tezacaftor ivacaftor
produc posit data two phase trial march fda approv
februari european approv came novemb brand
name symkevi expect orkambi symdeko wide adopt
cystic fibrosi patient homozyg mutat world-wide
improv potenc orkambi symdeko homozygot
effect patient one copi allel vertex
advanc second gener corrector clinic develop act
synergist lumacaftor tezacaftor complet correct
fold defect cftr tripl combin contain tezacaftor
ivacaftor second-gener once-daili corrector produc impress
phase data support nda file juli ema file
world-wide launch appear like tripl regimen appear repres true
breakthrough treatment improv qualiti life extend life
span patient cystic fibrosi world-wide moreov
second-gener corrector expect patent protect
vertex franchis long commerci life model assum earli
launch cystic fibrosi patient one vertex therapi
drive almost franchis sale dcf-base price target
file approv eu
possibl in-licens acquisit addit product candid
possibl approv
phase ii data first corrector
possibl initi phase ii poc trial fsg
possibl initi data phase i/ii studi sickl cell diseas beta-thalassemia
like releas data phase ii tezacaftor
possibl ema approv eu
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient per patient patient gate gate penetr patient per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling lncome exclud soe exclud soe expens net share share cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
